Pharma News

Worlds poor to get pneumonia vaccines at affordable cost

In a novel agreement, two global pharma majors have planned to make available their top-selling pneumonia vaccines at one-eighth of the market rates to save lives of poor children in developing countries.

Every day, 4,384 people, mostly children below the age of five, die due to preventable pneumococcal diseases, primarily pneumonia and meningitis. Most of these deaths, 1.6 million in a year, occur in some of the world’s poorest countries.

CPhI China to be held in Shanghai from June 2 to 4

Shanghai will be playing host to UBM International Media events CPhI, P-MEC, ICSE and BioPh From June 2 to 4. While CPhI will be focusing on intermediates and APIs markets, ICSE is for contract services and P-MEC exhibitors offer a complete range of pharma machinery and equipment. BioPh is aimed at those who provide bio-solutions for pharma.

Last year’s events attracted more than 23,000 attendees from 102 countries and more than 1,600 exhibitors, 127 of which were international companies.

LCT gets approval to advance to phase-II human trial with Diabecell

Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, has received approval to advance to the next phase of its New Zealand phase-II human clinical trial with its groundbreaking Diabecell. The approval follows a positive assessment from the New Zealand Data Safety and Monitoring Board of the first four patients to receive its Diabecell implants.

Allergan, Serenity Pharma enter global pact for the treatment of nocturia

Allergan, Inc. and Serenity Pharmaceuticals, LLC announced a global agreement for the development and commercialization of Ser-120, a phase III investigational drug currently in clinical development for the treatment of nocturia, a common yet often under-diagnosed urological disorder in adults characterized by frequent urination at night time.

Karnataka govt establishes 30 Special Courts to expedite spurious drug cases

Aiming to expedite cases pertaining to spurious and substandard drugs in the state, the Karnataka government with the consent of chief justice of Karnataka High Court has constituted 30 Special Courts in 30 districts. This notification comes in the wake of the powers conferred under Section 36 AB(1)of the Drugs & Cosmetics (Amended) Act, 2008.

Pages